Eagle Global Advisors LLC Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Eagle Global Advisors LLC purchased 95,180 shares of Lantheus Holdings, valued at approximately $9.29 million, marking their first stake in the company.
• Several institutional investors, including Janus Henderson Group and Farallon Capital Management, significantly increased their holdings in Lantheus by over 70% in the last quarter.
• Analysts are mixed on Lantheus stock, with price targets ranging from $70 to $117, while the stock has a current consensus rating of "Moderate Buy."

Eagle Global Advisors LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 95,180 shares of the medical equipment provider's stock, valued at approximately $9,290,000. Eagle Global Advisors LLC owned approximately 0.14% of Lantheus as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of LNTH. Russell Investments Group Ltd. grew its holdings in shares of Lantheus by 16.8% during the fourth quarter. Russell Investments Group Ltd. now owns 16,955 shares of the medical equipment provider's stock valued at $1,517,000 after purchasing an additional 2,443 shares during the last quarter. Legal & General Group Plc lifted its position in Lantheus by 2.1% in the fourth quarter. Legal & General Group Plc now owns 151,550 shares of the medical equipment provider's stock worth $13,558,000 after purchasing an additional 3,117 shares during the period. Raymond James Financial Inc. acquired a new stake in Lantheus in the fourth quarter worth approximately $36,183,000. Townsquare Capital LLC acquired a new stake in shares of Lantheus during the 4th quarter valued at $1,108,000. Finally, Granite Investment Partners LLC lifted its position in shares of Lantheus by 3.2% during the 4th quarter. Granite Investment Partners LLC now owns 51,149 shares of the medical equipment provider's stock valued at $4,576,000 after acquiring an additional 1,579 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LNTH. Truist Financial set a $63.00 price objective on Lantheus and gave the company a "hold" rating in a research report on Monday. B. Riley reduced their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Mizuho reduced their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. Finally, William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $105.50.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company's stock, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.00% of the stock is owned by insiders.

Lantheus Stock Down 3.9%

Shares of NASDAQ LNTH traded down $2.17 during mid-day trading on Tuesday, reaching $53.90. The company had a trading volume of 2,950,662 shares, compared to its average volume of 2,049,958. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The stock has a market capitalization of $3.66 billion, a PE ratio of 14.34 and a beta of 0.14. The stock's 50 day moving average is $75.41 and its 200-day moving average is $86.26.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%. The company had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. During the same period last year, the company posted $1.80 earnings per share. The company's revenue was down 4.1% compared to the same quarter last year. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.